Preclinical development of kinetin as a safe error-prone SARS-CoV-2 antiviral able to attenuate virus-induced inflammation
Orally available antivirals against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are necessary because of the continuous circulation of new variants that challenge immunized individuals. Because severe COVID-19 is a virus-triggered immune and inflammatory dysfunction, molecules endow...
Saved in:
| Published in | Nature communications Vol. 14; no. 1; pp. 199 - 17 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
Nature Publishing Group UK
13.01.2023
Nature Publishing Group Nature Portfolio |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Orally available antivirals against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are necessary because of the continuous circulation of new variants that challenge immunized individuals. Because severe COVID-19 is a virus-triggered immune and inflammatory dysfunction, molecules endowed with both antiviral and anti-inflammatory activity are highly desirable. We identified here that kinetin (MB-905) inhibits the in vitro replication of SARS-CoV-2 in human hepatic and pulmonary cell lines. On infected monocytes, MB-905 reduced virus replication, IL-6 and TNFα levels. MB-905 is converted into its triphosphate nucleotide to inhibit viral RNA synthesis and induce error-prone virus replication. Coinhibition of SARS-CoV-2 exonuclease, a proofreading enzyme that corrects erroneously incorporated nucleotides during viral RNA replication, potentiated the inhibitory effect of MB-905. MB-905 shows good oral absorption, its metabolites are stable, achieving long-lasting plasma and lung concentrations, and this drug is not mutagenic nor cardiotoxic in acute and chronic treatments. SARS-CoV-2-infected hACE-mice and hamsters treated with MB-905 show decreased viral replication, lung necrosis, hemorrhage and inflammation. Because kinetin is clinically investigated for a rare genetic disease at regimens beyond the predicted concentrations of antiviral/anti-inflammatory inhibition, our investigation suggests the opportunity for the rapid clinical development of a new antiviral substance for the treatment of COVID-19.
The search for antivirals against SARS-CoV-2 continue due to the emergence of variants of concerns, able to escape the vaccinal humoral response. In this work, authors pre-clinically explore the potential of kinetin against SARS-CoV-2, which could be used alone or in combination with other antivirals. |
|---|---|
| AbstractList | Orally available antivirals against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are necessary because of the continuous circulation of new variants that challenge immunized individuals. Because severe COVID-19 is a virus-triggered immune and inflammatory dysfunction, molecules endowed with both antiviral and anti-inflammatory activity are highly desirable. We identified here that kinetin (MB-905) inhibits the in vitro replication of SARS-CoV-2 in human hepatic and pulmonary cell lines. On infected monocytes, MB-905 reduced virus replication, IL-6 and TNFα levels. MB-905 is converted into its triphosphate nucleotide to inhibit viral RNA synthesis and induce error-prone virus replication. Coinhibition of SARS-CoV-2 exonuclease, a proofreading enzyme that corrects erroneously incorporated nucleotides during viral RNA replication, potentiated the inhibitory effect of MB-905. MB-905 shows good oral absorption, its metabolites are stable, achieving long-lasting plasma and lung concentrations, and this drug is not mutagenic nor cardiotoxic in acute and chronic treatments. SARS-CoV-2-infected hACE-mice and hamsters treated with MB-905 show decreased viral replication, lung necrosis, hemorrhage and inflammation. Because kinetin is clinically investigated for a rare genetic disease at regimens beyond the predicted concentrations of antiviral/anti-inflammatory inhibition, our investigation suggests the opportunity for the rapid clinical development of a new antiviral substance for the treatment of COVID-19.Orally available antivirals against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are necessary because of the continuous circulation of new variants that challenge immunized individuals. Because severe COVID-19 is a virus-triggered immune and inflammatory dysfunction, molecules endowed with both antiviral and anti-inflammatory activity are highly desirable. We identified here that kinetin (MB-905) inhibits the in vitro replication of SARS-CoV-2 in human hepatic and pulmonary cell lines. On infected monocytes, MB-905 reduced virus replication, IL-6 and TNFα levels. MB-905 is converted into its triphosphate nucleotide to inhibit viral RNA synthesis and induce error-prone virus replication. Coinhibition of SARS-CoV-2 exonuclease, a proofreading enzyme that corrects erroneously incorporated nucleotides during viral RNA replication, potentiated the inhibitory effect of MB-905. MB-905 shows good oral absorption, its metabolites are stable, achieving long-lasting plasma and lung concentrations, and this drug is not mutagenic nor cardiotoxic in acute and chronic treatments. SARS-CoV-2-infected hACE-mice and hamsters treated with MB-905 show decreased viral replication, lung necrosis, hemorrhage and inflammation. Because kinetin is clinically investigated for a rare genetic disease at regimens beyond the predicted concentrations of antiviral/anti-inflammatory inhibition, our investigation suggests the opportunity for the rapid clinical development of a new antiviral substance for the treatment of COVID-19. Orally available antivirals against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are necessary because of the continuous circulation of new variants that challenge immunized individuals. Because severe COVID-19 is a virus-triggered immune and inflammatory dysfunction, molecules endowed with both antiviral and anti-inflammatory activity are highly desirable. We identified here that kinetin (MB-905) inhibits the in vitro replication of SARS-CoV-2 in human hepatic and pulmonary cell lines. On infected monocytes, MB-905 reduced virus replication, IL-6 and TNFα levels. MB-905 is converted into its triphosphate nucleotide to inhibit viral RNA synthesis and induce error-prone virus replication. Coinhibition of SARS-CoV-2 exonuclease, a proofreading enzyme that corrects erroneously incorporated nucleotides during viral RNA replication, potentiated the inhibitory effect of MB-905. MB-905 shows good oral absorption, its metabolites are stable, achieving long-lasting plasma and lung concentrations, and this drug is not mutagenic nor cardiotoxic in acute and chronic treatments. SARS-CoV-2-infected hACE-mice and hamsters treated with MB-905 show decreased viral replication, lung necrosis, hemorrhage and inflammation. Because kinetin is clinically investigated for a rare genetic disease at regimens beyond the predicted concentrations of antiviral/anti-inflammatory inhibition, our investigation suggests the opportunity for the rapid clinical development of a new antiviral substance for the treatment of COVID-19. The search for antivirals against SARS-CoV-2 continue due to the emergence of variants of concerns, able to escape the vaccinal humoral response. In this work, authors pre-clinically explore the potential of kinetin against SARS-CoV-2, which could be used alone or in combination with other antivirals. Orally available antivirals against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are necessary because of the continuous circulation of new variants that challenge immunized individuals. Because severe COVID-19 is a virus-triggered immune and inflammatory dysfunction, molecules endowed with both antiviral and anti-inflammatory activity are highly desirable. We identified here that kinetin (MB-905) inhibits the in vitro replication of SARS-CoV-2 in human hepatic and pulmonary cell lines. On infected monocytes, MB-905 reduced virus replication, IL-6 and TNFα levels. MB-905 is converted into its triphosphate nucleotide to inhibit viral RNA synthesis and induce error-prone virus replication. Coinhibition of SARS-CoV-2 exonuclease, a proofreading enzyme that corrects erroneously incorporated nucleotides during viral RNA replication, potentiated the inhibitory effect of MB-905. MB-905 shows good oral absorption, its metabolites are stable, achieving long-lasting plasma and lung concentrations, and this drug is not mutagenic nor cardiotoxic in acute and chronic treatments. SARS-CoV-2-infected hACE-mice and hamsters treated with MB-905 show decreased viral replication, lung necrosis, hemorrhage and inflammation. Because kinetin is clinically investigated for a rare genetic disease at regimens beyond the predicted concentrations of antiviral/anti-inflammatory inhibition, our investigation suggests the opportunity for the rapid clinical development of a new antiviral substance for the treatment of COVID-19.The search for antivirals against SARS-CoV-2 continue due to the emergence of variants of concerns, able to escape the vaccinal humoral response. In this work, authors pre-clinically explore the potential of kinetin against SARS-CoV-2, which could be used alone or in combination with other antivirals. Orally available antivirals against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are necessary because of the continuous circulation of new variants that challenge immunized individuals. Because severe COVID-19 is a virus-triggered immune and inflammatory dysfunction, molecules endowed with both antiviral and anti-inflammatory activity are highly desirable. We identified here that kinetin (MB-905) inhibits the in vitro replication of SARS-CoV-2 in human hepatic and pulmonary cell lines. On infected monocytes, MB-905 reduced virus replication, IL-6 and TNFα levels. MB-905 is converted into its triphosphate nucleotide to inhibit viral RNA synthesis and induce error-prone virus replication. Coinhibition of SARS-CoV-2 exonuclease, a proofreading enzyme that corrects erroneously incorporated nucleotides during viral RNA replication, potentiated the inhibitory effect of MB-905. MB-905 shows good oral absorption, its metabolites are stable, achieving long-lasting plasma and lung concentrations, and this drug is not mutagenic nor cardiotoxic in acute and chronic treatments. SARS-CoV-2-infected hACE-mice and hamsters treated with MB-905 show decreased viral replication, lung necrosis, hemorrhage and inflammation. Because kinetin is clinically investigated for a rare genetic disease at regimens beyond the predicted concentrations of antiviral/anti-inflammatory inhibition, our investigation suggests the opportunity for the rapid clinical development of a new antiviral substance for the treatment of COVID-19. The search for antivirals against SARS-CoV-2 continue due to the emergence of variants of concerns, able to escape the vaccinal humoral response. In this work, authors pre-clinically explore the potential of kinetin against SARS-CoV-2, which could be used alone or in combination with other antivirals. Abstract Orally available antivirals against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are necessary because of the continuous circulation of new variants that challenge immunized individuals. Because severe COVID-19 is a virus-triggered immune and inflammatory dysfunction, molecules endowed with both antiviral and anti-inflammatory activity are highly desirable. We identified here that kinetin (MB-905) inhibits the in vitro replication of SARS-CoV-2 in human hepatic and pulmonary cell lines. On infected monocytes, MB-905 reduced virus replication, IL-6 and TNFα levels. MB-905 is converted into its triphosphate nucleotide to inhibit viral RNA synthesis and induce error-prone virus replication. Coinhibition of SARS-CoV-2 exonuclease, a proofreading enzyme that corrects erroneously incorporated nucleotides during viral RNA replication, potentiated the inhibitory effect of MB-905. MB-905 shows good oral absorption, its metabolites are stable, achieving long-lasting plasma and lung concentrations, and this drug is not mutagenic nor cardiotoxic in acute and chronic treatments. SARS-CoV-2-infected hACE-mice and hamsters treated with MB-905 show decreased viral replication, lung necrosis, hemorrhage and inflammation. Because kinetin is clinically investigated for a rare genetic disease at regimens beyond the predicted concentrations of antiviral/anti-inflammatory inhibition, our investigation suggests the opportunity for the rapid clinical development of a new antiviral substance for the treatment of COVID-19. |
| ArticleNumber | 199 |
| Author | Chaves, Ian Meira Guimarães, Pedro Pires Goulart Fintelman-Rodrigues, Natalia Andrade, Edineia L. Pinho, Vagner D. Ferreira, André C. Momo, Patrícia B. Costa, Vivian Vasconcelos Gesto, João S. M. Fadanni, Guilherme P. Marcon, Rodrigo Marques, Naiani F. Viola, João P. B. Queiroz-Junior, Celso Martins Guimarães, Lays Cordeiro Temerozo, Jairo R. Calixto, João B. Pereira-Dutra, Filipe Bozza, Patrícia T. Potrich, Francine B. Siqueira-Junior, Jarbas Souza, Thiago Moreno L. Aguillón, Anderson R. Sacramento, Carolina Q. Bou-Habib, Dumith Chequer Heller, Melina Santos, Adara A. Macedo-Junior, Sergio Tolouei, Sara E. L. Mattos, Mayara Dias, Suelen S. G. Rabi, Jaime A. Chaves, Otavio A. Setim, Cristina F. Teixeira, Mauro Martins |
| Author_xml | – sequence: 1 givenname: Thiago Moreno L. orcidid: 0000-0003-2212-3899 surname: Souza fullname: Souza, Thiago Moreno L. email: thiago.moreno@fiocruz.br organization: Laboratório de Imunofarmacologia, Oswaldo Cruz Institute, Fundação Oswaldo Cruz (Fiocruz), National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Fiocruz – sequence: 2 givenname: Vagner D. orcidid: 0000-0002-6278-4176 surname: Pinho fullname: Pinho, Vagner D. organization: Microbiológica Química e Farmacêutica, Doutor Nicanor – sequence: 3 givenname: Cristina F. surname: Setim fullname: Setim, Cristina F. organization: Centro de Inovação e Ensaios Pré-clínicos and National Institute for Science and Technology on Innovation in Medicines and Identification of New Therapeutics Targets (INCT-INOVAMED). Avenida Luiz Boiteux Piazza – sequence: 4 givenname: Carolina Q. surname: Sacramento fullname: Sacramento, Carolina Q. organization: Laboratório de Imunofarmacologia, Oswaldo Cruz Institute, Fundação Oswaldo Cruz (Fiocruz), National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Fiocruz – sequence: 5 givenname: Rodrigo surname: Marcon fullname: Marcon, Rodrigo organization: Centro de Inovação e Ensaios Pré-clínicos and National Institute for Science and Technology on Innovation in Medicines and Identification of New Therapeutics Targets (INCT-INOVAMED). Avenida Luiz Boiteux Piazza – sequence: 6 givenname: Natalia surname: Fintelman-Rodrigues fullname: Fintelman-Rodrigues, Natalia organization: Laboratório de Imunofarmacologia, Oswaldo Cruz Institute, Fundação Oswaldo Cruz (Fiocruz), National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Fiocruz – sequence: 7 givenname: Otavio A. orcidid: 0000-0001-6211-7659 surname: Chaves fullname: Chaves, Otavio A. organization: Laboratório de Imunofarmacologia, Oswaldo Cruz Institute, Fundação Oswaldo Cruz (Fiocruz), National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Fiocruz – sequence: 8 givenname: Melina surname: Heller fullname: Heller, Melina organization: Centro de Inovação e Ensaios Pré-clínicos and National Institute for Science and Technology on Innovation in Medicines and Identification of New Therapeutics Targets (INCT-INOVAMED). Avenida Luiz Boiteux Piazza – sequence: 9 givenname: Jairo R. orcidid: 0000-0002-8092-2149 surname: Temerozo fullname: Temerozo, Jairo R. organization: Laboratório de Imunofarmacologia, Oswaldo Cruz Institute, Fundação Oswaldo Cruz (Fiocruz), National Institute for Science and Technology on Neuroimmunomodulation (INCT/NIM), Oswaldo Cruz Institute, Fiocruz, Laboratório de Pesquisa sobre o Timo, Oswaldo Cruz Institute, Fiocruz – sequence: 10 givenname: André C. surname: Ferreira fullname: Ferreira, André C. organization: Laboratório de Imunofarmacologia, Oswaldo Cruz Institute, Fundação Oswaldo Cruz (Fiocruz), National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Fiocruz, Universidade Iguaçu – sequence: 11 givenname: Mayara surname: Mattos fullname: Mattos, Mayara organization: Laboratório de Imunofarmacologia, Oswaldo Cruz Institute, Fundação Oswaldo Cruz (Fiocruz), National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Fiocruz – sequence: 12 givenname: Patrícia B. orcidid: 0000-0003-4570-3394 surname: Momo fullname: Momo, Patrícia B. organization: Microbiológica Química e Farmacêutica, Doutor Nicanor – sequence: 13 givenname: Suelen S. G. orcidid: 0000-0002-3104-0983 surname: Dias fullname: Dias, Suelen S. G. organization: Laboratório de Imunofarmacologia, Oswaldo Cruz Institute, Fundação Oswaldo Cruz (Fiocruz) – sequence: 14 givenname: João S. M. surname: Gesto fullname: Gesto, João S. M. organization: Laboratório de Imunofarmacologia, Oswaldo Cruz Institute, Fundação Oswaldo Cruz (Fiocruz), National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Fiocruz – sequence: 15 givenname: Filipe orcidid: 0000-0003-1917-2876 surname: Pereira-Dutra fullname: Pereira-Dutra, Filipe organization: Laboratório de Imunofarmacologia, Oswaldo Cruz Institute, Fundação Oswaldo Cruz (Fiocruz) – sequence: 16 givenname: João P. B. surname: Viola fullname: Viola, João P. B. organization: Program of Immunology and Tumor Biology, Brazilian National Cancer Institute (INCA), Rua André Cavalcanti 37 – sequence: 17 givenname: Celso Martins surname: Queiroz-Junior fullname: Queiroz-Junior, Celso Martins organization: Centro de Pesquisa e Desenvolvimento de Fármacos, Instituto de Ciências Biológicas, (ICB), Universidade Federal de Minas Gerais (UFMG) – sequence: 18 givenname: Lays Cordeiro surname: Guimarães fullname: Guimarães, Lays Cordeiro organization: Department of Physiology and Biophysics, Institute of Biological Sciences, Universidade Federal de Minas Gerais – sequence: 19 givenname: Ian Meira surname: Chaves fullname: Chaves, Ian Meira organization: Centro de Pesquisa e Desenvolvimento de Fármacos, Instituto de Ciências Biológicas, (ICB), Universidade Federal de Minas Gerais (UFMG) – sequence: 20 givenname: Pedro Pires Goulart surname: Guimarães fullname: Guimarães, Pedro Pires Goulart organization: Department of Physiology and Biophysics, Institute of Biological Sciences, Universidade Federal de Minas Gerais – sequence: 21 givenname: Vivian Vasconcelos surname: Costa fullname: Costa, Vivian Vasconcelos organization: Centro de Pesquisa e Desenvolvimento de Fármacos, Instituto de Ciências Biológicas, (ICB), Universidade Federal de Minas Gerais (UFMG) – sequence: 22 givenname: Mauro Martins surname: Teixeira fullname: Teixeira, Mauro Martins organization: Centro de Pesquisa e Desenvolvimento de Fármacos, Instituto de Ciências Biológicas, (ICB), Universidade Federal de Minas Gerais (UFMG) – sequence: 23 givenname: Dumith Chequer orcidid: 0000-0003-0552-9045 surname: Bou-Habib fullname: Bou-Habib, Dumith Chequer organization: National Institute for Science and Technology on Neuroimmunomodulation (INCT/NIM), Oswaldo Cruz Institute, Fiocruz, Laboratório de Pesquisa sobre o Timo, Oswaldo Cruz Institute, Fiocruz – sequence: 24 givenname: Patrícia T. orcidid: 0000-0001-8349-9529 surname: Bozza fullname: Bozza, Patrícia T. organization: Laboratório de Imunofarmacologia, Oswaldo Cruz Institute, Fundação Oswaldo Cruz (Fiocruz) – sequence: 25 givenname: Anderson R. surname: Aguillón fullname: Aguillón, Anderson R. organization: Microbiológica Química e Farmacêutica, Doutor Nicanor – sequence: 26 givenname: Jarbas orcidid: 0000-0002-4647-1997 surname: Siqueira-Junior fullname: Siqueira-Junior, Jarbas organization: Centro de Inovação e Ensaios Pré-clínicos and National Institute for Science and Technology on Innovation in Medicines and Identification of New Therapeutics Targets (INCT-INOVAMED). Avenida Luiz Boiteux Piazza – sequence: 27 givenname: Sergio surname: Macedo-Junior fullname: Macedo-Junior, Sergio organization: Centro de Inovação e Ensaios Pré-clínicos and National Institute for Science and Technology on Innovation in Medicines and Identification of New Therapeutics Targets (INCT-INOVAMED). Avenida Luiz Boiteux Piazza – sequence: 28 givenname: Edineia L. surname: Andrade fullname: Andrade, Edineia L. organization: Centro de Inovação e Ensaios Pré-clínicos and National Institute for Science and Technology on Innovation in Medicines and Identification of New Therapeutics Targets (INCT-INOVAMED). Avenida Luiz Boiteux Piazza – sequence: 29 givenname: Guilherme P. orcidid: 0000-0002-3082-8322 surname: Fadanni fullname: Fadanni, Guilherme P. organization: Centro de Inovação e Ensaios Pré-clínicos and National Institute for Science and Technology on Innovation in Medicines and Identification of New Therapeutics Targets (INCT-INOVAMED). Avenida Luiz Boiteux Piazza – sequence: 30 givenname: Sara E. L. surname: Tolouei fullname: Tolouei, Sara E. L. organization: Centro de Inovação e Ensaios Pré-clínicos and National Institute for Science and Technology on Innovation in Medicines and Identification of New Therapeutics Targets (INCT-INOVAMED). Avenida Luiz Boiteux Piazza – sequence: 31 givenname: Francine B. surname: Potrich fullname: Potrich, Francine B. organization: Centro de Inovação e Ensaios Pré-clínicos and National Institute for Science and Technology on Innovation in Medicines and Identification of New Therapeutics Targets (INCT-INOVAMED). Avenida Luiz Boiteux Piazza – sequence: 32 givenname: Adara A. surname: Santos fullname: Santos, Adara A. organization: Centro de Inovação e Ensaios Pré-clínicos and National Institute for Science and Technology on Innovation in Medicines and Identification of New Therapeutics Targets (INCT-INOVAMED). Avenida Luiz Boiteux Piazza – sequence: 33 givenname: Naiani F. surname: Marques fullname: Marques, Naiani F. organization: Centro de Inovação e Ensaios Pré-clínicos and National Institute for Science and Technology on Innovation in Medicines and Identification of New Therapeutics Targets (INCT-INOVAMED). Avenida Luiz Boiteux Piazza – sequence: 34 givenname: João B. orcidid: 0000-0003-4041-7153 surname: Calixto fullname: Calixto, João B. email: joao.calixto@cienp.org.br organization: Centro de Inovação e Ensaios Pré-clínicos and National Institute for Science and Technology on Innovation in Medicines and Identification of New Therapeutics Targets (INCT-INOVAMED). Avenida Luiz Boiteux Piazza – sequence: 35 givenname: Jaime A. surname: Rabi fullname: Rabi, Jaime A. email: jrabi@microbiologica.ind.br organization: Microbiológica Química e Farmacêutica, Doutor Nicanor |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36639383$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9ks9vFCEUxyemxtbaf8CDIfHiBeXHDDAXk2ajtUkTjVWvhIU3K-sMrMBs4v71xd1aWw9ygbz35cN7j-_T5ijEAE3znJLXlHD1Jre0FRITxjHveqbw7lFzwkhLMZWMH907HzdnOa9JXbynqm2fNMdcCN5zxU-a3acEdvTBWzMiB1sY42aCUFAc0A8foPiATEYGZTMAgpRiwptUS0HX55-v8SJ-wwyZUPzWp0owyxFQiciUAmE2BVCNzxn74GYLDvkwjGaaTPExPGseD2bMcHa7nzZf37_7sviArz5eXC7Or7DtWlJwCxyY5B0FRjtphAQlLQy9cEAEG9RSOCtrY5IMTPYtdZY6pxS11FgrXMdPm8sD10Wz1pvkJ5N-6Wi83gdiWmmTircjaOm6zi0Hq7jpW865UQwAJOEdt9CTvrLeHlibeTmBs3VSte0H0IeZ4L_rVdzqXnEpRVsBr24BKf6cIRc9-WxhHE2AOGfNpOhk_TQqqvTlP9J1nFOoo9qrGBNU0qpiB5VNMecEw10xlOjfTtEHp-jqFL13it7VSy_ut3F35Y8vqoAfBLmmwgrS37f_g70BNqDM5A |
| CitedBy_id | crossref_primary_10_1007_s00044_023_03115_w crossref_primary_10_3389_fimmu_2024_1378591 crossref_primary_10_1039_D3CS00709J crossref_primary_10_3390_v16040651 crossref_primary_10_3390_v16060826 |
| Cites_doi | 10.1126/sciimmunol.abj1750 10.1016/S2213-2600(21)00287-3 10.1016/j.jinf.2021.08.031 10.1006/bbrc.1999.1669 10.1002/jmr.2782 10.1007/s00109-006-0137-2 10.1038/s41422-020-0282-0 10.1203/PDR.0b013e318194fd52 10.4103/0976-0105.177703 10.1007/s00405-020-05965-1 10.1038/s42003-022-03101-9 10.1001/jamainternmed.2021.6203 10.1056/NEJMoa2021436 10.1203/PDR.0b013e31822e1825 10.1016/j.cell.2013.07.030 10.1128/JVI.01276-21 10.15585/mmwr.mm7037e1 10.1093/hmg/ddh046 10.1126/scitranslmed.abl7430 10.1002/jmv.25728 10.1021/ml2000615 10.1006/bbrc.2000.3928 10.1007/s12032-020-1338-1 10.1128/CMR.00102-15 10.1016/j.ymthe.2022.03.014 10.1038/s41586-020-2196-x 10.1002/eji.202070035 10.1016/j.celrep.2020.107940 10.1016/S1473-3099(20)30120-1 10.1093/nar/gkab1303 10.1126/scitranslmed.abb5883 10.1038/s41594-021-00651-0 10.1261/rna.064048.117 10.1126/science.abb7498 10.1001/jamaneurol.2020.1127 10.1016/S2213-2600(20)30076-X 10.1016/j.pharmthera.2020.107512 10.1007/s40262-013-0093-2 10.1038/s41467-022-29104-y 10.1093/cid/ciaa410 10.1016/S0140-6736(20)30566-3 10.1177/2040206618775243 10.1016/S2666-5247(20)30004-5 10.1093/infdis/jiab247 10.1093/jac/dkab072 10.1038/s41598-020-73641-9 10.1101/2020.08.11.242834 10.1101/2022.06.28.497978 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2023 2023. The Author(s). The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2023 – notice: 2023. The Author(s). – notice: The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7QL 7QP 7QR 7SN 7SS 7ST 7T5 7T7 7TM 7TO 7X7 7XB 88E 8AO 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABUWG AFKRA ARAPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. LK8 M0S M1P M7P P5Z P62 P64 PIMPY PQEST PQQKQ PQUKI RC3 SOI 7X8 5PM DOA |
| DOI | 10.1038/s41467-023-35928-z |
| DatabaseName | Springer Nature OA Free Journals Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Chemoreception Abstracts Ecology Abstracts Entomology Abstracts (Full archive) Environment Abstracts Immunology Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Health & Medical Collection (Proquest) ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central Advanced Technologies & Aerospace Database (1962 - current) ProQuest Central Essentials Biological Science Collection AUTh Library subscriptions: ProQuest Central Technology Collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection (Proquest) (PQ_SDU_P3) ProQuest Health & Medical Complete (Alumni) Biological Sciences Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Biological Science Database ProQuest Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition Genetics Abstracts Environment Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database ProQuest Central Student Oncogenes and Growth Factors Abstracts ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection Environmental Sciences and Pollution Management Health Research Premium Collection Natural Science Collection Biological Science Collection Chemoreception Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) ProQuest Medical Library (Alumni) Advanced Technologies & Aerospace Collection ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Entomology Abstracts ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Engineering Research Database ProQuest One Academic Calcium & Calcified Tissue Abstracts Technology Collection Technology Research Database ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central Genetics Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) AIDS and Cancer Research Abstracts ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Immunology Abstracts Environment Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE Publicly Available Content Database CrossRef |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: 8FG name: ProQuest Technology Collection url: https://search.proquest.com/technologycollection1 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 2041-1723 |
| EndPage | 17 |
| ExternalDocumentID | oai_doaj_org_article_7d55dbfc83a94333a82eee70353ce909 10_1038_s41467_023_35928_z 36639383 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (Carlos Chagas Filho Foundation for Research Support in the State of Rio de Janeiro) funderid: https://doi.org/10.13039/501100004586 – fundername: Ministry of Science, Technology and Innovation | Conselho Nacional de Desenvolvimento Científico e Tecnológico (National Council for Scientific and Technological Development) funderid: https://doi.org/10.13039/501100003593 – fundername: ; |
| GroupedDBID | --- 0R~ 39C 3V. 53G 5VS 70F 7X7 88E 8AO 8FE 8FG 8FH 8FI 8FJ AAHBH AAJSJ ABUWG ACGFO ACGFS ACIWK ACMJI ACPRK ACSMW ADBBV ADFRT ADRAZ AENEX AFKRA AFRAH AHMBA AJTQC ALIPV ALMA_UNASSIGNED_HOLDINGS AMTXH AOIJS ARAPS ASPBG AVWKF AZFZN BBNVY BCNDV BENPR BGLVJ BHPHI BPHCQ BVXVI C6C CCPQU DIK EBLON EBS EE. EMOBN F5P FEDTE FYUFA GROUPED_DOAJ HCIFZ HMCUK HVGLF HYE HZ~ KQ8 LK8 M1P M48 M7P M~E NAO O9- OK1 P2P P62 PIMPY PQQKQ PROAC PSQYO RNS RNT RNTTT RPM SNYQT SV3 TSG UKHRP CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QL 7QP 7QR 7SN 7SS 7ST 7T5 7T7 7TM 7TO 7XB 8FD 8FK AZQEC C1K DWQXO FR3 GNUQQ H94 K9. P64 PQEST PQUKI RC3 SOI 7X8 5PM |
| ID | FETCH-LOGICAL-c540t-4e3e27351e2157a67e87cef96de062f8b6dc791870f27941dc1dd881c1acc6d53 |
| IEDL.DBID | RPM |
| ISSN | 2041-1723 |
| IngestDate | Tue Oct 22 15:08:40 EDT 2024 Tue Sep 17 21:30:31 EDT 2024 Sat Oct 26 04:01:49 EDT 2024 Thu Oct 10 21:05:08 EDT 2024 Fri Aug 23 02:30:51 EDT 2024 Sat Nov 02 11:56:41 EDT 2024 Fri Oct 11 20:48:07 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | 2023. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c540t-4e3e27351e2157a67e87cef96de062f8b6dc791870f27941dc1dd881c1acc6d53 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0003-4041-7153 0000-0002-4647-1997 0000-0001-6211-7659 0000-0003-0552-9045 0000-0002-3104-0983 0000-0003-2212-3899 0000-0002-6278-4176 0000-0003-4570-3394 0000-0002-8092-2149 0000-0003-1917-2876 0000-0001-8349-9529 0000-0002-3082-8322 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837764/ |
| PMID | 36639383 |
| PQID | 2765226171 |
| PQPubID | 546298 |
| PageCount | 17 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_7d55dbfc83a94333a82eee70353ce909 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9837764 proquest_miscellaneous_2765772316 proquest_journals_2765226171 crossref_primary_10_1038_s41467_023_35928_z pubmed_primary_36639383 springer_journals_10_1038_s41467_023_35928_z |
| PublicationCentury | 2000 |
| PublicationDate | 2023-01-13 |
| PublicationDateYYYYMMDD | 2023-01-13 |
| PublicationDate_xml | – month: 01 year: 2023 text: 2023-01-13 day: 13 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Nature communications |
| PublicationTitleAbbrev | Nat Commun |
| PublicationTitleAlternate | Nat Commun |
| PublicationYear | 2023 |
| Publisher | Nature Publishing Group UK Nature Publishing Group Nature Portfolio |
| Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group – name: Nature Portfolio |
| References | Scobie (CR3) 2021; 70 Tré-Hardy (CR8) 2021; 83 Mao (CR28) 2020; 77 Gao (CR11) 2020; 368 Dong, Du, Gardner (CR1) 2020; 20 Baddock (CR16) 2022; 50 Jockusch (CR15) 2020; 10 Slusarczyk, Serpi, Pertusati (CR12) 2018; 26 Spyropoulos (CR29) 2021; 181 De Clercq, Li (CR49) 2016; 29 Nair, Jacob (CR41) 2016; 7 Geers (CR4) 2021; 6 Bastos, Ranzani, Souza, Hamacher, Bozza (CR5) 2021; 9 Andrade (CR56) 2021; 95 CR7 CR48 Xu (CR25) 2020; 8 Li, Bai, Hashikawa (CR26) 2020; 92 Olsen, Siboska, Clark, Rattan (CR46) 1999; 265 Gandhi (CR6) 2022; 13 Horby (CR30) 2021; 384 Lukkarila (CR51) 2011; 2 Westhof, Yusupov, Yusupova (CR35) 2019; 32 Slaugenhaupt (CR43) 2004; 13 Gold-von Simson (CR40) 2009; 65 Sheahan (CR9) 2020; 12 Wyler (CR31) 2022; 30 Hims (CR42) 2007; 85 Barciszewski, Mielcarek, Stobiecki, Siboska, Clark (CR44) 2000; 279 CR18 Park, Thwaites, Openshaw (CR2) 2020; 50 CR55 Wang (CR37) 2022; 5 CR54 CR52 Lechien (CR27) 2020; 277 Fischer (CR20) 2022; 14 CR50 Cottrell, Hadzic, Kashuba (CR38) 2013; 52 Shiraki, Daikoku (CR34) 2020; 209 Chu (CR33) 2020; 71 Dulińska-Litewka (CR45) 2020; 37 Kabinger (CR17) 2021; 28 Axelrod (CR39) 2011; 70 Chu (CR32) 2020; 1 Pruijssers (CR10) 2020; 32 Hertz (CR47) 2013; 154 Wang (CR14) 2020; 30 CR23 CR22 CR21 Zhou (CR19) 2021; 224 Wölfel (CR53) 2020; 581 Zhou (CR24) 2020; 395 Sacramento (CR13) 2021; 76 Garg, Heinemann (CR36) 2018; 24 35928_CR21 35928_CR22 35928_CR23 YC Li (35928_CR26) 2020; 92 H Chu (35928_CR32) 2020; 1 LS Bastos (35928_CR5) 2021; 9 E Westhof (35928_CR35) 2019; 32 JR Lechien (35928_CR27) 2020; 277 35928_CR7 AJ Pruijssers (35928_CR10) 2020; 32 G Gold-von Simson (35928_CR40) 2009; 65 J Dulińska-Litewka (35928_CR45) 2020; 37 A Garg (35928_CR36) 2018; 24 E Wyler (35928_CR31) 2022; 30 E De Clercq (35928_CR49) 2016; 29 HM Scobie (35928_CR3) 2021; 70 J Barciszewski (35928_CR44) 2000; 279 FB Axelrod (35928_CR39) 2011; 70 WA Fischer 2nd (35928_CR20) 2022; 14 M Wang (35928_CR14) 2020; 30 MM Hims (35928_CR42) 2007; 85 JL Lukkarila (35928_CR51) 2011; 2 D Geers (35928_CR4) 2021; 6 S Zhou (35928_CR19) 2021; 224 E Dong (35928_CR1) 2020; 20 A Andrade (35928_CR56) 2021; 95 F Zhou (35928_CR24) 2020; 395 HT Baddock (35928_CR16) 2022; 50 35928_CR48 M Park (35928_CR2) 2020; 50 R Wölfel (35928_CR53) 2020; 581 M Slusarczyk (35928_CR12) 2018; 26 F Kabinger (35928_CR17) 2021; 28 P Horby (35928_CR30) 2021; 384 SA Slaugenhaupt (35928_CR43) 2004; 13 X Wang (35928_CR37) 2022; 5 35928_CR54 35928_CR55 NT Hertz (35928_CR47) 2013; 154 H Chu (35928_CR33) 2020; 71 Z Xu (35928_CR25) 2020; 8 35928_CR18 A Olsen (35928_CR46) 1999; 265 S Gandhi (35928_CR6) 2022; 13 Y Gao (35928_CR11) 2020; 368 K Shiraki (35928_CR34) 2020; 209 AC Spyropoulos (35928_CR29) 2021; 181 ML Cottrell (35928_CR38) 2013; 52 CQ Sacramento (35928_CR13) 2021; 76 AB Nair (35928_CR41) 2016; 7 35928_CR50 TP Sheahan (35928_CR9) 2020; 12 S Jockusch (35928_CR15) 2020; 10 L Mao (35928_CR28) 2020; 77 35928_CR52 M Tré-Hardy (35928_CR8) 2021; 83 |
| References_xml | – volume: 6 start-page: eabj1750 year: 2021 ident: CR4 article-title: SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees publication-title: Sci. Immunol. doi: 10.1126/sciimmunol.abj1750 contributor: fullname: Geers – ident: CR22 – volume: 9 start-page: e82 year: 2021 end-page: e83 ident: CR5 article-title: COVID-19 hospital admissions: Brazil’s first and second waves compared publication-title: Lancet Respir. Med. doi: 10.1016/S2213-2600(21)00287-3 contributor: fullname: Bozza – volume: 83 start-page: 559 year: 2021 end-page: 564 ident: CR8 article-title: Immunogenicity of mRNA-1273 COVID vaccine after 6 months surveillance in health care workers; a third dose is necessary publication-title: J. Infect. doi: 10.1016/j.jinf.2021.08.031 contributor: fullname: Tré-Hardy – volume: 265 start-page: 499 year: 1999 end-page: 502 ident: CR46 article-title: N(6)-Furfuryladenine, kinetin, protects against Fenton reaction-mediated oxidative damage to DNA publication-title: Biochem. Biophys. Res. Commun. doi: 10.1006/bbrc.1999.1669 contributor: fullname: Rattan – volume: 32 start-page: e2782 year: 2019 ident: CR35 article-title: The multiple flavors of GoU pairs in RNA publication-title: J. Mol. Recognit. doi: 10.1002/jmr.2782 contributor: fullname: Yusupova – volume: 85 start-page: 149 year: 2007 end-page: 161 ident: CR42 article-title: Therapeutic potential and mechanism of kinetin as a treatment for the human splicing disease familial dysautonomia publication-title: J. Mol. Med. doi: 10.1007/s00109-006-0137-2 contributor: fullname: Hims – volume: 30 start-page: 269 year: 2020 end-page: 271 ident: CR14 article-title: Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro publication-title: Cell Res. doi: 10.1038/s41422-020-0282-0 contributor: fullname: Wang – volume: 65 start-page: 341 year: 2009 end-page: 346 ident: CR40 article-title: Kinetin in familial dysautonomia carriers: implications for a new therapeutic strategy targeting mRNA splicing publication-title: Pediatr. Res. doi: 10.1203/PDR.0b013e318194fd52 contributor: fullname: Gold-von Simson – ident: CR54 – volume: 7 start-page: 27 year: 2016 end-page: 31 ident: CR41 article-title: A simple practice guide for dose conversion between animals and human publication-title: J. Basic Clin. Pharm. doi: 10.4103/0976-0105.177703 contributor: fullname: Jacob – volume: 277 start-page: 2251 year: 2020 end-page: 2261 ident: CR27 article-title: Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study publication-title: Eur. Arch. Otorhinolaryngol. doi: 10.1007/s00405-020-05965-1 contributor: fullname: Lechien – volume: 5 start-page: 154 year: 2022 ident: CR37 article-title: Combination of antiviral drugs inhibits SARS-CoV-2 polymerase and exonuclease and demonstrates COVID-19 therapeutic potential in viral cell culture publication-title: Commun. Biol. doi: 10.1038/s42003-022-03101-9 contributor: fullname: Wang – volume: 181 start-page: 1612 year: 2021 end-page: 1620 ident: CR29 article-title: Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: the HEP-COVID randomized clinical trial publication-title: JAMA Intern. Med. doi: 10.1001/jamainternmed.2021.6203 contributor: fullname: Spyropoulos – volume: 384 start-page: 693 year: 2021 end-page: 704 ident: CR30 article-title: Dexamethasone in hospitalized patients with Covid-19 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2021436 contributor: fullname: Horby – ident: CR21 – volume: 70 start-page: 480 year: 2011 end-page: 483 ident: CR39 article-title: Kinetin improves IKBKAP mRNA splicing in patients with familial dysautonomia publication-title: Pediatr. Res. doi: 10.1203/PDR.0b013e31822e1825 contributor: fullname: Axelrod – volume: 154 start-page: 737 year: 2013 end-page: 747 ident: CR47 article-title: A neo-substrate that amplifies catalytic activity of Parkinson’s-disease-related kinase PINK1 publication-title: Cell doi: 10.1016/j.cell.2013.07.030 contributor: fullname: Hertz – volume: 95 start-page: e0127621 year: 2021 ident: CR56 article-title: A biosafety level 2 mouse model for studying betacoronavirus-induced acute lung damage and systemic manifestations publication-title: J. Virol. doi: 10.1128/JVI.01276-21 contributor: fullname: Andrade – volume: 70 start-page: 1284 year: 2021 end-page: 1290 ident: CR3 article-title: Monitoring incidence of COVID-19 cases, hospitalizations, and deaths, by vaccination status - 13 U.S. jurisdictions, April 4-July 17, 2021 publication-title: MMWR Morb. Mortal. Wkly. Rep. doi: 10.15585/mmwr.mm7037e1 contributor: fullname: Scobie – volume: 13 start-page: 429 year: 2004 end-page: 436 ident: CR43 article-title: Rescue of a human mRNA splicing defect by the plant cytokinin kinetin publication-title: Hum. Mol. Genet. doi: 10.1093/hmg/ddh046 contributor: fullname: Slaugenhaupt – ident: CR50 – volume: 14 start-page: eabl7430 year: 2022 ident: CR20 article-title: A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.abl7430 contributor: fullname: Fischer – volume: 92 start-page: 552 year: 2020 end-page: 555 ident: CR26 article-title: The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients publication-title: J. Med. Virol. doi: 10.1002/jmv.25728 contributor: fullname: Hashikawa – volume: 2 start-page: 577 year: 2011 end-page: 582 ident: CR51 article-title: Identification of NAE inhibitors exhibiting potent activity in leukemia cells: exploring the structural determinants of NAE specificity publication-title: ACS Med. Chem. Lett. doi: 10.1021/ml2000615 contributor: fullname: Lukkarila – volume: 279 start-page: 69 year: 2000 end-page: 73 ident: CR44 article-title: Identification of 6-furfuryladenine (kinetin) in human urine publication-title: Biochem. Biophys. Res. Commun. doi: 10.1006/bbrc.2000.3928 contributor: fullname: Clark – volume: 37 year: 2020 ident: CR45 article-title: Could the kinetin riboside be used to inhibit human prostate cell epithelial-mesenchymal transition? publication-title: Med. Oncol. doi: 10.1007/s12032-020-1338-1 contributor: fullname: Dulińska-Litewka – volume: 29 start-page: 695 year: 2016 end-page: 747 ident: CR49 article-title: Approved antiviral drugs over the past 50 years publication-title: Clin. Microbiol. Rev. doi: 10.1128/CMR.00102-15 contributor: fullname: Li – ident: CR18 – volume: 30 start-page: 1952 year: 2022 end-page: 1965 ident: CR31 article-title: Key benefits of dexamethasone and antibody treatment in COVID-19 hamster models revealed by single cell transcriptomics publication-title: Mol. Ther. doi: 10.1016/j.ymthe.2022.03.014 contributor: fullname: Wyler – volume: 581 start-page: 465 year: 2020 end-page: 469 ident: CR53 article-title: Virological assessment of hospitalized patients with COVID-2019 publication-title: Nature doi: 10.1038/s41586-020-2196-x contributor: fullname: Wölfel – volume: 50 start-page: 308 year: 2020 end-page: 311 ident: CR2 article-title: COVID-19: lessons from SARS and MERS publication-title: Eur. J. Immunol. doi: 10.1002/eji.202070035 contributor: fullname: Openshaw – volume: 32 start-page: 107940 year: 2020 ident: CR10 article-title: Remdesivir inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in Mice publication-title: Cell Rep. doi: 10.1016/j.celrep.2020.107940 contributor: fullname: Pruijssers – volume: 20 start-page: 533 year: 2020 end-page: 534 ident: CR1 article-title: An interactive web-based dashboard to track COVID-19 in real time publication-title: Lancet Infect. Dis. doi: 10.1016/S1473-3099(20)30120-1 contributor: fullname: Gardner – volume: 50 start-page: 1484 year: 2022 end-page: 1500 ident: CR16 article-title: Characterization of the SARS-CoV-2 ExoN (nsp14ExoN-nsp10) complex: implications for its role in viral genome stability and inhibitor identification publication-title: Nucleic Acids Res. doi: 10.1093/nar/gkab1303 contributor: fullname: Baddock – volume: 12 start-page: eabb5883 year: 2020 ident: CR9 article-title: An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.abb5883 contributor: fullname: Sheahan – volume: 28 start-page: 740 year: 2021 end-page: 746 ident: CR17 article-title: Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis publication-title: Nat. Struct. Mol. Biol. doi: 10.1038/s41594-021-00651-0 contributor: fullname: Kabinger – ident: CR23 – volume: 24 start-page: 209 year: 2018 end-page: 218 ident: CR36 article-title: A novel form of RNA double helix based on G·U and C·A(+) wobble base pairing publication-title: RNA doi: 10.1261/rna.064048.117 contributor: fullname: Heinemann – volume: 368 start-page: 779 year: 2020 end-page: 782 ident: CR11 article-title: Structure of the RNA-dependent RNA polymerase from COVID-19 virus publication-title: Science doi: 10.1126/science.abb7498 contributor: fullname: Gao – volume: 77 start-page: 683 year: 2020 end-page: 690 ident: CR28 article-title: Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China publication-title: JAMA Neurol. doi: 10.1001/jamaneurol.2020.1127 contributor: fullname: Mao – ident: CR48 – volume: 8 start-page: 420 year: 2020 end-page: 422 ident: CR25 article-title: Pathological findings of COVID-19 associated with acute respiratory distress syndrome publication-title: Lancet Respir. Med. doi: 10.1016/S2213-2600(20)30076-X contributor: fullname: Xu – volume: 209 start-page: 107512 year: 2020 ident: CR34 article-title: Favipiravir, an anti-influenza drug against life-threatening RNA virus infections publication-title: Pharmacol. Ther. doi: 10.1016/j.pharmthera.2020.107512 contributor: fullname: Daikoku – ident: CR52 – volume: 52 start-page: 981 year: 2013 end-page: 994 ident: CR38 article-title: Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir publication-title: Clin. Pharmacokinet. doi: 10.1007/s40262-013-0093-2 contributor: fullname: Kashuba – volume: 13 year: 2022 ident: CR6 article-title: De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report publication-title: Nat. Commun. doi: 10.1038/s41467-022-29104-y contributor: fullname: Gandhi – volume: 71 start-page: 1400 year: 2020 end-page: 1409 ident: CR33 article-title: Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19 publication-title: Clin. Infect. Dis. doi: 10.1093/cid/ciaa410 contributor: fullname: Chu – volume: 395 start-page: 1054 year: 2020 end-page: 1062 ident: CR24 article-title: Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study publication-title: Lancet doi: 10.1016/S0140-6736(20)30566-3 contributor: fullname: Zhou – volume: 26 start-page: 2040206618775243 year: 2018 ident: CR12 article-title: Phosphoramidates and phosphonamidates (ProTides) with antiviral activity publication-title: Antivir. Chem. Chemother. doi: 10.1177/2040206618775243 contributor: fullname: Pertusati – volume: 1 start-page: e14 year: 2020 end-page: e23 ident: CR32 article-title: Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study publication-title: Lancet Microbe doi: 10.1016/S2666-5247(20)30004-5 contributor: fullname: Chu – volume: 224 start-page: 415 year: 2021 end-page: 419 ident: CR19 article-title: β-d-N4-hydroxycytidine inhibits SARS-CoV-2 through lethal mutagenesis but is also mutagenic to mammalian cells publication-title: J. Infect. Dis. doi: 10.1093/infdis/jiab247 contributor: fullname: Zhou – ident: CR55 – ident: CR7 – volume: 76 start-page: 1874 year: 2021 end-page: 1885 ident: CR13 article-title: In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19 publication-title: J. Antimicrob. Chemother. doi: 10.1093/jac/dkab072 contributor: fullname: Sacramento – volume: 10 year: 2020 ident: CR15 article-title: Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir publication-title: Sci. Rep. doi: 10.1038/s41598-020-73641-9 contributor: fullname: Jockusch – ident: 35928_CR54 – volume: 30 start-page: 269 year: 2020 ident: 35928_CR14 publication-title: Cell Res. doi: 10.1038/s41422-020-0282-0 contributor: fullname: M Wang – volume: 13 year: 2022 ident: 35928_CR6 publication-title: Nat. Commun. doi: 10.1038/s41467-022-29104-y contributor: fullname: S Gandhi – volume: 224 start-page: 415 year: 2021 ident: 35928_CR19 publication-title: J. Infect. Dis. doi: 10.1093/infdis/jiab247 contributor: fullname: S Zhou – volume: 76 start-page: 1874 year: 2021 ident: 35928_CR13 publication-title: J. Antimicrob. Chemother. doi: 10.1093/jac/dkab072 contributor: fullname: CQ Sacramento – ident: 35928_CR48 – volume: 9 start-page: e82 year: 2021 ident: 35928_CR5 publication-title: Lancet Respir. Med. doi: 10.1016/S2213-2600(21)00287-3 contributor: fullname: LS Bastos – volume: 92 start-page: 552 year: 2020 ident: 35928_CR26 publication-title: J. Med. Virol. doi: 10.1002/jmv.25728 contributor: fullname: YC Li – ident: 35928_CR21 – volume: 30 start-page: 1952 year: 2022 ident: 35928_CR31 publication-title: Mol. Ther. doi: 10.1016/j.ymthe.2022.03.014 contributor: fullname: E Wyler – ident: 35928_CR50 doi: 10.1101/2020.08.11.242834 – volume: 368 start-page: 779 year: 2020 ident: 35928_CR11 publication-title: Science doi: 10.1126/science.abb7498 contributor: fullname: Y Gao – volume: 20 start-page: 533 year: 2020 ident: 35928_CR1 publication-title: Lancet Infect. Dis. doi: 10.1016/S1473-3099(20)30120-1 contributor: fullname: E Dong – volume: 12 start-page: eabb5883 year: 2020 ident: 35928_CR9 publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.abb5883 contributor: fullname: TP Sheahan – volume: 52 start-page: 981 year: 2013 ident: 35928_CR38 publication-title: Clin. Pharmacokinet. doi: 10.1007/s40262-013-0093-2 contributor: fullname: ML Cottrell – volume: 181 start-page: 1612 year: 2021 ident: 35928_CR29 publication-title: JAMA Intern. Med. doi: 10.1001/jamainternmed.2021.6203 contributor: fullname: AC Spyropoulos – ident: 35928_CR55 – volume: 28 start-page: 740 year: 2021 ident: 35928_CR17 publication-title: Nat. Struct. Mol. Biol. doi: 10.1038/s41594-021-00651-0 contributor: fullname: F Kabinger – volume: 37 year: 2020 ident: 35928_CR45 publication-title: Med. Oncol. doi: 10.1007/s12032-020-1338-1 contributor: fullname: J Dulińska-Litewka – volume: 50 start-page: 1484 year: 2022 ident: 35928_CR16 publication-title: Nucleic Acids Res. doi: 10.1093/nar/gkab1303 contributor: fullname: HT Baddock – volume: 384 start-page: 693 year: 2021 ident: 35928_CR30 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2021436 contributor: fullname: P Horby – volume: 6 start-page: eabj1750 year: 2021 ident: 35928_CR4 publication-title: Sci. Immunol. doi: 10.1126/sciimmunol.abj1750 contributor: fullname: D Geers – volume: 95 start-page: e0127621 year: 2021 ident: 35928_CR56 publication-title: J. Virol. doi: 10.1128/JVI.01276-21 contributor: fullname: A Andrade – ident: 35928_CR18 – volume: 26 start-page: 204020661877524 year: 2018 ident: 35928_CR12 publication-title: Antivir. Chem. Chemother. doi: 10.1177/2040206618775243 contributor: fullname: M Slusarczyk – volume: 32 start-page: e2782 year: 2019 ident: 35928_CR35 publication-title: J. Mol. Recognit. doi: 10.1002/jmr.2782 contributor: fullname: E Westhof – volume: 29 start-page: 695 year: 2016 ident: 35928_CR49 publication-title: Clin. Microbiol. Rev. doi: 10.1128/CMR.00102-15 contributor: fullname: E De Clercq – volume: 70 start-page: 480 year: 2011 ident: 35928_CR39 publication-title: Pediatr. Res. doi: 10.1203/PDR.0b013e31822e1825 contributor: fullname: FB Axelrod – volume: 279 start-page: 69 year: 2000 ident: 35928_CR44 publication-title: Biochem. Biophys. Res. Commun. doi: 10.1006/bbrc.2000.3928 contributor: fullname: J Barciszewski – ident: 35928_CR52 – volume: 581 start-page: 465 year: 2020 ident: 35928_CR53 publication-title: Nature doi: 10.1038/s41586-020-2196-x contributor: fullname: R Wölfel – volume: 7 start-page: 27 year: 2016 ident: 35928_CR41 publication-title: J. Basic Clin. Pharm. doi: 10.4103/0976-0105.177703 contributor: fullname: AB Nair – volume: 1 start-page: e14 year: 2020 ident: 35928_CR32 publication-title: Lancet Microbe doi: 10.1016/S2666-5247(20)30004-5 contributor: fullname: H Chu – volume: 395 start-page: 1054 year: 2020 ident: 35928_CR24 publication-title: Lancet doi: 10.1016/S0140-6736(20)30566-3 contributor: fullname: F Zhou – ident: 35928_CR23 – volume: 71 start-page: 1400 year: 2020 ident: 35928_CR33 publication-title: Clin. Infect. Dis. doi: 10.1093/cid/ciaa410 contributor: fullname: H Chu – volume: 5 start-page: 154 year: 2022 ident: 35928_CR37 publication-title: Commun. Biol. doi: 10.1038/s42003-022-03101-9 contributor: fullname: X Wang – ident: 35928_CR7 doi: 10.1101/2022.06.28.497978 – volume: 77 start-page: 683 year: 2020 ident: 35928_CR28 publication-title: JAMA Neurol. doi: 10.1001/jamaneurol.2020.1127 contributor: fullname: L Mao – volume: 13 start-page: 429 year: 2004 ident: 35928_CR43 publication-title: Hum. Mol. Genet. doi: 10.1093/hmg/ddh046 contributor: fullname: SA Slaugenhaupt – volume: 70 start-page: 1284 year: 2021 ident: 35928_CR3 publication-title: MMWR Morb. Mortal. Wkly. Rep. doi: 10.15585/mmwr.mm7037e1 contributor: fullname: HM Scobie – volume: 154 start-page: 737 year: 2013 ident: 35928_CR47 publication-title: Cell doi: 10.1016/j.cell.2013.07.030 contributor: fullname: NT Hertz – volume: 14 start-page: eabl7430 year: 2022 ident: 35928_CR20 publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.abl7430 contributor: fullname: WA Fischer 2nd – volume: 32 start-page: 107940 year: 2020 ident: 35928_CR10 publication-title: Cell Rep. doi: 10.1016/j.celrep.2020.107940 contributor: fullname: AJ Pruijssers – volume: 83 start-page: 559 year: 2021 ident: 35928_CR8 publication-title: J. Infect. doi: 10.1016/j.jinf.2021.08.031 contributor: fullname: M Tré-Hardy – volume: 10 year: 2020 ident: 35928_CR15 publication-title: Sci. Rep. doi: 10.1038/s41598-020-73641-9 contributor: fullname: S Jockusch – volume: 2 start-page: 577 year: 2011 ident: 35928_CR51 publication-title: ACS Med. Chem. Lett. doi: 10.1021/ml2000615 contributor: fullname: JL Lukkarila – ident: 35928_CR22 – volume: 209 start-page: 107512 year: 2020 ident: 35928_CR34 publication-title: Pharmacol. Ther. doi: 10.1016/j.pharmthera.2020.107512 contributor: fullname: K Shiraki – volume: 24 start-page: 209 year: 2018 ident: 35928_CR36 publication-title: RNA doi: 10.1261/rna.064048.117 contributor: fullname: A Garg – volume: 65 start-page: 341 year: 2009 ident: 35928_CR40 publication-title: Pediatr. Res. doi: 10.1203/PDR.0b013e318194fd52 contributor: fullname: G Gold-von Simson – volume: 277 start-page: 2251 year: 2020 ident: 35928_CR27 publication-title: Eur. Arch. Otorhinolaryngol. doi: 10.1007/s00405-020-05965-1 contributor: fullname: JR Lechien – volume: 50 start-page: 308 year: 2020 ident: 35928_CR2 publication-title: Eur. J. Immunol. doi: 10.1002/eji.202070035 contributor: fullname: M Park – volume: 265 start-page: 499 year: 1999 ident: 35928_CR46 publication-title: Biochem. Biophys. Res. Commun. doi: 10.1006/bbrc.1999.1669 contributor: fullname: A Olsen – volume: 8 start-page: 420 year: 2020 ident: 35928_CR25 publication-title: Lancet Respir. Med. doi: 10.1016/S2213-2600(20)30076-X contributor: fullname: Z Xu – volume: 85 start-page: 149 year: 2007 ident: 35928_CR42 publication-title: J. Mol. Med. doi: 10.1007/s00109-006-0137-2 contributor: fullname: MM Hims |
| SSID | ssj0000391844 |
| Score | 2.480502 |
| Snippet | Orally available antivirals against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are necessary because of the continuous circulation of new... Abstract Orally available antivirals against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are necessary because of the continuous circulation... The search for antivirals against SARS-CoV-2 continue due to the emergence of variants of concerns, able to escape the vaccinal humoral response. In this work,... |
| SourceID | doaj pubmedcentral proquest crossref pubmed springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 199 |
| SubjectTerms | 13/106 38/23 38/77 38/88 38/91 59 631/154/436/2388 631/326/596/1296 631/326/596/4130 631/45/500 64/86 9/25 Animals Anti-inflammatory agents Antiviral agents Antiviral Agents - pharmacology Antiviral Agents - therapeutic use Cell lines Coronaviruses COVID-19 Editing Exonuclease Genetic disorders Hamsters Hemorrhage Humanities and Social Sciences Humans Immune response (humoral) Immunization Inflammation Inflammation - drug therapy Interleukin 6 Kinetin Kinetin - pharmacology Lungs Metabolites Mice Monocytes multidisciplinary Necrosis Nucleotides Proofreading Replication Ribonucleic acid RNA SARS-CoV-2 Science Science (multidisciplinary) Severe acute respiratory syndrome coronavirus 2 Transcription Tumor necrosis factor-α Viral diseases Virus Replication Viruses |
| SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NaxUxEA9SELyI365WieBNQzebbD6OtViKoIi10lvIJhN8WHbl7b5D31_fye6-1z4_8OI1yWGY32-S35DMhJDXRmIU-UxegJpJAMO8CpJB_jgsVakEm6uRP35SJ2fyw3l9fuOrr_wmbGoPPDnuQMe6jk0KRngrhRDeVACAPK1FADuX7pX2RjI17sHCYuoi5yqZUpiDXo57Ah5RTNS2Mmy9cxKNDfv_pDJ_fyz5y43peBAd3yN3ZwVJDyfL75Nb0D4gt6c_JS8fkvVn3MPmckcar58E0S7RHygph0VLfU897X0CCstlt2RoTgv09PDLKTvqvrGKorsX-fXvBc2VVXToaG7D2a5QmFIcX_UMU3kkRaRIUOTUVP_4iJwdv_96dMLmDxZYQKE2IDQCUL7UHPDg115pMDpAsipCqapkGhWDRkfqMlUYtzwGHqMxPHAfgoq1eEz2WjTwKaGIr4gJEWlsg5oEGhMigiS55knyVBbkzcbZ7ufUR8ON99_CuAkah9C4ERq3Lsi7jMd2Ze6BPQ4gM9zMDPcvZhRkf4OmmwOzd5VWWXGiWQV5tZ3GkMr3JL6FbjWtwaRDcFWQJxP4W0sEKjSLWX1B9A4tdkzdnWkX38e23dYIrZUsyNsNga7N-rsrnv0PVzwnd6rM_JIzLvbJ3rBcwQsUU0PzcoybK7LQHNQ priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection (Proquest) dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9QwEA96Ivgifls9JYJvGq5p0iR9kvPwOARFPE_2LaTJRBelPdvug_vXO2m7u6xfr02h0_xmJr8k80HIcyPRilxSXoCSSQDDnPKSQWocFouYQ5Wykd-9V2cX8u2iXMwHbv0cVrnxiaOjDq1PZ-RHhVaJKnDNX13-YKlrVLpdnVtoXCXXeJGrFNKlF3p7xpKqnxsp51yZXJijXo6eARcqJsqqMGy9tx6NZfv_xjX_DJn87d50XI5Ob5GbM4-kxxPwt8kVaO6Q61NnyZ93yfoDerI56ZGGXWAQbSP9hsRyWDbU9dTR3kWg0HVtx1CcBuj58cdzdtJ-ZgXFSV-mGODvNOVX0aGlqRhns0J6SvH5qme4oUfVCBTVFDVryoK8Ry5O33w6OWNzmwXmka4NCJAAJDElB1z-tVMajPYQKxUgV0U0tQpe40TqPBZovTx4HoIx3HPnvQqluE8OGhTwIaGIsgjRI75VjcwEauMDuhSJqEXJY56RF5vJtpdTNQ073oILYydoLEJjR2jsOiOvEx7bN1Ml7PFB232xs2FZHcoy1NEb4SophHCmAAD8aClQjrzKyOEGTTubZ293ypSRZ9thNKx0W-IaaFfTO7j1EFxl5MEE_lYSgTytwr19RvSeWuyJuj_SLL-OxbsrI7RWMiMvNwq0E-vfU_Ho_3_xmNwokk7nnHFxSA6GbgVPkCwN9dPRIn4BQ5IUHg priority: 102 providerName: ProQuest – databaseName: Scholars Portal Open Access Journals dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3di9QwEB_OE-VexG-rp0TwTaNN0ybpg8h5eByCIp4r91a6yeRcPFptu-DtX--kH3usri--Ji0ZZn6T_IZkZgCemZS8qAzgRcx4imh4qWzKMTQO84mPMQ_ZyB8-quNZ-v40O92Bqd3RqMB2a2gX-knNmvOXv35evCGHfz2kjJtXbdq7O50-XGZ5YvjqClxNUorUw1O-ke73O7PMKaBJx9yZ7b_uwXVJp3Aujdw4qvqK_tto6N-vKf-4Uu1PqqObcGOkmOxgwMQt2MHqNlwbmk5e3IHVJ9rkxnxI5i7fDLHas-_EObtFxcqWlawtPTJsmrrhJE6F7OTg8wk_rL_yhJE9FuF58DkLqVesq1mo01ktibkyGl-2nGJ9Qo1jpFMC3ZAgeRdmR---HB7zsQMDt8TkOrKdROI3mUBiBrpUGo226HPlMFaJN3PlrCad6tgn5NjCWeGcMcKK0lrlMnkPdisS8AEwAoB03pLp8zmRFpwb62i3SYUWPhU-juD5pOzix1Boo-gvyKUpBisVZKWit1KxiuBtsMf6y1Akux-om7Ni9LlCuyxzc2-NLHNCgyxNgoi0aCZJjjiPYH-yZjEBr0i0CpSUxIrg6XqafC5cpJQV1svhG4pKpFAR3B-Mv5ZkAk8EegMWG6JuzlSLb31d79xIrVUawYsJQJdi_VsVD_97oUewlwTkx4ILuQ-7XbPEx0SxuvmT3m9-A0tGJQU priority: 102 providerName: Scholars Portal – databaseName: Springer Nature OA Free Journals dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Nb9QwELWgCIkLKp9NW5CRuIFFHDu2cywrqgoJhChFvVmOPRYrUFJtsgf213ecZLcKlAPX2FFG82Y8b2LPmJDXRqIXuWS8ACWTAIY55SWDdHFYLGIOVapG_vRZnV3Ij5fl5dQmJ9XCzPbvhXnXycGVMbIwUVaFYZu75B7GYJOOby3UYvc_JXU6N1JOdTG3vzqLPUOL_tt45d_HI__YIx1Cz-k-eThxRnoygvyI3IHmMbk_3iL5-wnZfMFVaypwpOHmEBBtI_2JJLJfNtR11NHORaCwWrUrhuI0QM9Pvp6zRfudFRQVvEznfX_RVEtF-5amxpvNGqkoxefrjmHyjmYQKJokWtFY8fiUXJx--LY4Y9OVCswjNesRDAFIWEoOGOq1UxqM9hArFSBXRTS1Cl6jInUeC_RUHjwPwRjuufNehVI8I3sNCnhAKCIqQvSIZVUjC4Ha-IDLh-SaR8ljnpE3W2Xbq7Fzhh12vIWxIzQWobEDNHaTkfcJj93M1PV6eIDGYCcnsjqUZaijN8JVUgjhTAEA-NFSoBx5lZHjLZp2csXOFloljoliZeTVbhidKO2MuAba9TgH0wzBVUaej-DvJBHIySrM4zOiZ2YxE3U-0ix_DI26K8z-tZIZebs1oBux_q2Kw_-bfkQeFMnGc864OCZ7_WoNL5Ao9fXLwUOuATO0Dag priority: 102 providerName: Springer Nature |
| Title | Preclinical development of kinetin as a safe error-prone SARS-CoV-2 antiviral able to attenuate virus-induced inflammation |
| URI | https://link.springer.com/article/10.1038/s41467-023-35928-z https://www.ncbi.nlm.nih.gov/pubmed/36639383 https://www.proquest.com/docview/2765226171 https://www.proquest.com/docview/2765772316 https://pubmed.ncbi.nlm.nih.gov/PMC9837764 https://doaj.org/article/7d55dbfc83a94333a82eee70353ce909 |
| Volume | 14 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9swDBbaDht6Gfaety7QgN02NZYlS_IxDZoVAVIEzTr0Zth6dMFau8jjsPz6UbKdLntcdrEB2YAJ8aP40SIphD4oDlZUePBamxJurSKF0JxYf3CYS1xsM1-NPDkXZ5d8fJVe7aG0q4UJSfu6nB9XN7fH1fxbyK28u9X9Lk-sP50MM4iqpOD9fbQPAP0lRA_LL8sgauFtgUzMVH_Jw3IA3omwNEsU2RyiRwxcbcYU2_FHoW3_37jmnymTv-2bBnc0eoIetzwSDxp5n6I9Wz1DD5uTJX88R5sprGRt0SM294lBuHb4OxDL1bzCxRIXeFk4i-1iUS8IiFNZPBtczMiw_koSDJM-9znAN9jXV-FVjX0zzmoN9BTD-HpJIKAHaBgMMAVkNVWQL9Dl6PTL8Iy0xywQDXRtBQpiFkhMSi24f1kIaZXU1mXC2FgkTpXCaAlzKmOXgPVSo6kxSlFNC62FSdlLdFCBgK8RBi0z4zToNyuBmdhSaQNLCqeSOk5dHKGP3WTnd003jTzsgjOVN1rKQUt50FK-idCJ18f2Td8JOwzUi-u8xUMuTZqa0mnFiowzxgqVWGvhoykDOeIsQkedNvPWPJd5IoXnnSBWhN5vH4Nh-d2SorL1unkHQg9GRYReNcrfStKBJ0JyBxY7ou4-ASyH5t0tdiP0qQPQvVj_noo3__2ht-gw8ciPKaHsCB2sFmv7DnjUquyB9VxJuKrR5x56MBiMZ2O4n5yeTy9gdCiGvfCHAq4TrnrByn4CGuQk2Q |
| link.rule.ids | 230,315,730,783,787,867,888,2109,2228,12068,12777,21400,24330,27936,27937,31731,31732,33385,33386,33756,33757,41132,42201,43322,43612,43817,51588,53804,53806,74073,74363,74630 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagFYIL4k2ggJG4gdU4dmLnhNqq1QLtquoD9WYl9hhWoKQk2QP76xkn2V0tr6ttKRN_M-PPj5kh5I2WaEVFUF6AlEkAzYrMSgahcJhPfAx5iEY-mWaTS_nxKr0aD9za8Vnl0if2jtrVNpyR7yYqC1SBK_7--gcLVaPC7epYQuMm2Q6pqnDztb1_OD09W52yhPznWsoxWiYWereVvW_ApYqJNE80W2ysSH3i_r-xzT8fTf52c9ovSEf3yN2RSdK9Afr75AZUD8itobbkz4dkcYq-bAx7pG79NIjWnn5DatnNKlq0tKBt4YFC09QNQ3EqoOd7Z-fsoP7MEorTPguvgL_TEGFFu5qGdJzVHAkqxfZ5y3BLj8rhKCoq6tYQB_mIXB4dXhxM2FhogVkkbB1CJABpTMoBCYAqMgVaWfB55iDOEq_LzFmFE6lin6D9cme5c1pzywtrM5eKx2SrQgGfEoo4C-ctIpyXyE2g1NahU5GIm5fcxxF5u5xscz3k0zD9PbjQZoDGIDSmh8YsIrIf8FiNDLmw-4a6-WJG0zLKpakrvdWiyKUQotAJAOBHU4FyxHlEdpZomtFAW7NWp4i8XnWjaYX7kqKCej6Mwc2H4FlEngzgryQRyNRy3N1HRG2oxYaomz3V7GufvjvXQqlMRuTdUoHWYv17Kp79_y9ekduTi5Njc_xh-uk5uZME_Y4542KHbHXNHF4gderKl6N9_AITrhh0 |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lj9MwELagKxAXxJvAAkbiBlbj2LGdE9pdtlpeVbXLor1ZiR9QgZIlaQ_01zNO3FbldY0tZeJvZvw5ngdCLxQHKyqD8jqXE-6cIqUwnLjQOMxnPnVFyEb-OBUn5_zdRX4R45-6GFa59om9o7aNCf_Ix5kUgSpQScc-hkXM3kxeX_4goYNUuGmN7TSuoj3JBUtHaO_weDo73fxxCbXQFecxcyZlatzx3k_AtkVYXmSKrHZ2p76I_9-Y558BlL_dovab0-QWuhlZJT4Y1OA2uuLqO-ja0Gfy5120moFfiymQ2G7DhHDj8TegmYt5jcsOl7grvcOubZuWgDi1w2cHp2fkqPlMMgwQzENE8Hccsq3wosGhNGe9BLKK4fmyI3C8B0WxGJQW9GzIibyHzifHn45OSGy6QAyQtwXAxRxQmpw6IAOyFNIpaZwvhHWpyLyqhDUSFlKmPgNbptZQa5WihpbGCJuz-2hUg4APEQbMmfUG0C4q4CmuUsaCg-GAoefUpwl6uV5sfTnU1tD9nThTeoBGAzS6h0avEnQY8NjMDHWx-wdN-0VHM9PS5rmtvFGsLDhjrFSZcw5emjOQIy0StL9GU0dj7fRWtRL0fDMMZhbuTsraNcthDhxEGBUJejCAv5GEAWsr4KSfILmjFjui7o7U8699Ke9CMSkFT9CrtQJtxfr3Ujz6_1c8Q9fBNPSHt9P3j9GNLKh3Sgll-2i0aJfuCbCoRfU0mscvKZMcog |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Preclinical+development+of+kinetin+as+a+safe+error-prone+SARS-CoV-2+antiviral+able+to+attenuate+virus-induced+inflammation&rft.jtitle=Nature+communications&rft.au=Souza%2C+Thiago+Moreno+L.&rft.au=Pinho%2C+Vagner+D.&rft.au=Setim%2C+Cristina+F.&rft.au=Sacramento%2C+Carolina+Q.&rft.date=2023-01-13&rft.pub=Nature+Publishing+Group+UK&rft.eissn=2041-1723&rft.volume=14&rft_id=info:doi/10.1038%2Fs41467-023-35928-z&rft_id=info%3Apmid%2F36639383&rft.externalDBID=PMC9837764 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2041-1723&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2041-1723&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2041-1723&client=summon |